Metoclopramide in the reduction of nausea and vomiting associated with combined chemotherapy.
The nausea and vomiting associated with combination chemotherapy is a serious cause of morbidity. Though widely used, metoclopramide has not previously been shown, in controlled studies, to be of benefit in reducing these side-effects. A double blind placebo-controlled randomized trial of IV and oral metoclopramide is reported, based on 117 courses of chemotherapy. Of 59 courses in which metoclopramide was given, vomiting was prevented in 28 (47%), compared with only 10 of 58 (17%) in the control group, a highly significant (P less than 0.001) improvement. The importance of adequate dosage of metoclopramide and the role of IV metoclopramide are emphasized.
D000970:Antineoplastic Agents / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D006801:Humans; D008787:Metoclopramide / Q000627:therapeutic use*; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control*; D009369:Neoplasms / Q000188:drug therapy*; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
D000970:Antineoplastic Agents; D008787:Metoclopramide